{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "name": "clv2.ipynb",
      "provenance": [],
      "collapsed_sections": [],
      "authorship_tag": "ABX9TyNmsYFFhaB9sRHs3x1oD/hj",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/chunribu/biotable/blob/main/clinvar_variation_release.xml.gz.to_json.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import gzip\n",
        "import xmltodict\n",
        "import json\n",
        "\n",
        "def xmlgz2json(fname, depth=2, **kwargs):\n",
        "    if not fname.endswith('.gz'):\n",
        "        return\n",
        "    global _n\n",
        "    _n = 0\n",
        "    def _callback(_,i):\n",
        "        global _n\n",
        "        if _n % 10000 == 0:\n",
        "            print(f'Parsing item: {_n}')\n",
        "        _n += 1\n",
        "        line = json.dumps(i)+'\\n'\n",
        "        fo.write(line.encode('ASCII'))\n",
        "        return True\n",
        "    fo = gzip.open(fname[:-3]+'.json.gz', 'a')\n",
        "    xmltodict.parse(gzip.GzipFile(fname), item_depth=depth, item_callback=_callback, **kwargs)"
      ],
      "metadata": {
        "id": "H58_C4N9EATv"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "xmlgz2json('test.xml.gz')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "wAgVn-orzupw",
        "outputId": "461fe7e8-c60a-4bd4-b359-807e0326888b"
      },
      "execution_count": 6,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Parsing item: 0\n",
            "Parsing item: 9999\n",
            "Parsing item: 19998\n",
            "Parsing item: 29997\n",
            "Parsing item: 39996\n",
            "Parsing item: 49995\n",
            "Parsing item: 59994\n",
            "Parsing item: 69993\n",
            "Parsing item: 79992\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!gzip -dc test.xml.json.gz|head"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "gIcLsibY1ye4",
        "outputId": "d477d008-f604-4322-e7dd-80504c3f7255"
      },
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{\"RecordStatus\": \"current\", \"Species\": \"Homo sapiens\", \"InterpretedRecord\": {\"SimpleAllele\": {\"@AlleleID\": \"15480\", \"@VariationID\": \"441\", \"GeneList\": {\"Gene\": {\"@Symbol\": \"BCAM\", \"@FullName\": \"basal cell adhesion molecule (Lutheran blood group)\", \"@GeneID\": \"4059\", \"@HGNC_ID\": \"HGNC:6722\", \"@Source\": \"submitted\", \"@RelationshipType\": \"asserted, but not computed\", \"Location\": {\"CytogeneticLocation\": \"19q13.32\", \"SequenceLocation\": [{\"@Assembly\": \"GRCh38\", \"@AssemblyAccessionVersion\": \"GCF_000001405.38\", \"@AssemblyStatus\": \"current\", \"@Chr\": \"19\", \"@Accession\": \"NC_000019.10\", \"@start\": \"44809059\", \"@stop\": \"44821421\", \"@display_start\": \"44809059\", \"@display_stop\": \"44821421\", \"@Strand\": \"+\"}, {\"@Assembly\": \"GRCh37\", \"@AssemblyAccessionVersion\": \"GCF_000001405.25\", \"@AssemblyStatus\": \"previous\", \"@Chr\": \"19\", \"@Accession\": \"NC_000019.9\", \"@start\": \"45312315\", \"@stop\": \"45324677\", \"@display_start\": \"45312315\", \"@display_stop\": \"45324677\", \"@Strand\": \"+\"}]}, \"OMIM\": \"612773\"}}, \"Name\": \"BCAM, EX3-4DEL\", \"VariantType\": \"Deletion\", \"Location\": {\"CytogeneticLocation\": \"19q13.2\"}, \"OtherNameList\": {\"Name\": \"EX3-4DEL\"}, \"XRefList\": {\"XRef\": {\"@Type\": \"Allelic variant\", \"@ID\": \"612773.0004\", \"@DB\": \"OMIM\"}}}, \"ReviewStatus\": \"no assertion criteria provided\", \"RCVList\": {\"RCVAccession\": {\"@Title\": \"BCAM, EX3-4DEL AND BLOOD GROUP--LUTHERAN NULL\", \"@DateLastEvaluated\": \"2007-03-01\", \"@ReviewStatus\": \"no assertion criteria provided\", \"@Interpretation\": \"Pathogenic\", \"@SubmissionCount\": \"1\", \"@Accession\": \"RCV000000470\", \"@Version\": \"4\", \"InterpretedConditionList\": {\"@TraitSetID\": \"125\", \"InterpretedCondition\": {\"@DB\": \"MedGen\", \"@ID\": \"C4017284\", \"#text\": \"BLOOD GROUP--LUTHERAN NULL\"}}}}, \"Interpretations\": {\"Interpretation\": {\"@DateLastEvaluated\": \"2007-03-01\", \"@NumberOfSubmissions\": \"1\", \"@NumberOfSubmitters\": \"1\", \"@Type\": \"Clinical significance\", \"Description\": \"Pathogenic\", \"Citation\": {\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"17319831\"}}, \"ConditionList\": {\"TraitSet\": {\"@ID\": \"125\", \"@Type\": \"Disease\", \"Trait\": {\"@ID\": \"9638\", \"@Type\": \"BloodGroup\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"BLOOD GROUP--LUTHERAN NULL\"}, \"XRef\": [{\"@Type\": \"Allelic variant\", \"@ID\": \"612773.0005\", \"@DB\": \"OMIM\"}, {\"@Type\": \"Allelic variant\", \"@ID\": \"612773.0006\", \"@DB\": \"OMIM\"}, {\"@Type\": \"Allelic variant\", \"@ID\": \"612773.0003\", \"@DB\": \"OMIM\"}, {\"@Type\": \"Allelic variant\", \"@ID\": \"612773.0004\", \"@DB\": \"OMIM\"}]}, \"XRef\": {\"@ID\": \"C4017284\", \"@DB\": \"MedGen\"}}}}}}, \"ClinicalAssertionList\": {\"ClinicalAssertion\": {\"@ID\": \"20619\", \"@DateCreated\": \"2011-01-25\", \"@DateLastUpdated\": \"2019-03-31\", \"@SubmissionDate\": \"2010-12-30\", \"ClinVarSubmissionID\": {\"@localKey\": \"612773.0004_BLOOD GROUP--LUTHERAN NULL\", \"@title\": \"BCAM, EX3-4DEL_BLOOD GROUP--LUTHERAN NULL\"}, \"ClinVarAccession\": {\"@Accession\": \"SCV000020619\", \"@Type\": \"SCV\", \"@Version\": \"3\", \"@SubmitterName\": \"OMIM\", \"@OrgID\": \"3\", \"@OrganizationCategory\": \"resource\"}, \"RecordStatus\": \"current\", \"ReviewStatus\": \"no assertion criteria provided\", \"Interpretation\": {\"@DateLastEvaluated\": \"2007-03-01\", \"Description\": \"Pathogenic\"}, \"Assertion\": \"variation to disease\", \"ObservedInList\": {\"ObservedIn\": {\"Sample\": {\"Origin\": \"germline\", \"Species\": \"human\", \"AffectedStatus\": \"not provided\"}, \"Method\": {\"MethodType\": \"literature only\"}, \"ObservedData\": {\"Attribute\": {\"@Type\": \"Description\", \"#text\": \"For discussion of the deletion of exons 3 and 4 in the BCAM gene that was found in compound heterozygous state in a patient with the Lutheran null blood group phenotype (247420) by Karamatic Crew et al. (2007), see 612773.0003.\"}, \"Citation\": {\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"17319831\"}}, \"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"247420\", \"@Type\": \"MIM\"}}}}, \"SimpleAllele\": {\"GeneList\": {\"Gene\": {\"@Symbol\": \"BCAM\"}}, \"Name\": \"BCAM, EX3-4DEL\", \"VariantType\": \"Variation\", \"OtherNameList\": {\"Name\": {\"@Type\": \"NonHGVS\", \"#text\": \"EX3-4DEL\"}}, \"XRefList\": {\"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"612773.0004\", \"@Type\": \"Allelic variant\"}}}, \"TraitSet\": {\"@Type\": \"Disease\", \"Trait\": {\"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"BLOOD GROUP--LUTHERAN NULL\"}}}}}}, \"TraitMappingList\": {\"TraitMapping\": {\"@ClinicalAssertionID\": \"20619\", \"@TraitType\": \"Disease\", \"@MappingType\": \"Name\", \"@MappingValue\": \"BLOOD GROUP--LUTHERAN NULL\", \"@MappingRef\": \"Preferred\", \"MedGen\": {\"@CUI\": \"C4017284\", \"@Name\": \"BLOOD GROUP--LUTHERAN NULL\"}}}}}\n",
            "{\"RecordStatus\": \"current\", \"Species\": \"Homo sapiens\", \"InterpretedRecord\": {\"SimpleAllele\": {\"@AlleleID\": \"18915\", \"@VariationID\": \"3876\", \"GeneList\": {\"Gene\": {\"@Symbol\": \"HEXB\", \"@FullName\": \"hexosaminidase subunit beta\", \"@GeneID\": \"3074\", \"@HGNC_ID\": \"HGNC:4879\", \"@Source\": \"submitted\", \"@RelationshipType\": \"asserted, but not computed\", \"Location\": {\"CytogeneticLocation\": \"5q13.3\", \"SequenceLocation\": [{\"@Assembly\": \"GRCh38\", \"@AssemblyAccessionVersion\": \"GCF_000001405.38\", \"@AssemblyStatus\": \"current\", \"@Chr\": \"5\", \"@Accession\": \"NC_000005.10\", \"@start\": \"74640023\", \"@stop\": \"74721288\", \"@display_start\": \"74640023\", \"@display_stop\": \"74721288\", \"@Strand\": \"+\"}, {\"@Assembly\": \"GRCh37\", \"@AssemblyAccessionVersion\": \"GCF_000001405.25\", \"@AssemblyStatus\": \"previous\", \"@Chr\": \"5\", \"@Accession\": \"NC_000005.9\", \"@start\": \"73980968\", \"@stop\": \"74017112\", \"@display_start\": \"73980968\", \"@display_stop\": \"74017112\", \"@Strand\": \"+\"}]}, \"OMIM\": \"606873\"}}, \"Name\": \"HEXB, 18-BP INS\", \"VariantType\": \"Insertion\", \"Location\": {\"CytogeneticLocation\": \"5q13\"}, \"OtherNameList\": {\"Name\": \"18-BP INS\"}, \"XRefList\": {\"XRef\": {\"@Type\": \"Allelic variant\", \"@ID\": \"606873.0003\", \"@DB\": \"OMIM\"}}}, \"ReviewStatus\": \"no assertion criteria provided\", \"RCVList\": {\"RCVAccession\": {\"@Title\": \"HEXB, 18-BP INS AND Hexosaminidase B (paris)\", \"@DateLastEvaluated\": \"1990-10-15\", \"@ReviewStatus\": \"no assertion criteria provided\", \"@Interpretation\": \"Pathogenic\", \"@SubmissionCount\": \"1\", \"@Accession\": \"RCV000004080\", \"@Version\": \"2\", \"InterpretedConditionList\": {\"@TraitSetID\": \"1061\", \"InterpretedCondition\": {\"@DB\": \"MedGen\", \"@ID\": \"C4016989\", \"#text\": \"Hexosaminidase B (paris)\"}}}}, \"Interpretations\": {\"Interpretation\": {\"@DateLastEvaluated\": \"1990-10-15\", \"@NumberOfSubmissions\": \"1\", \"@NumberOfSubmitters\": \"1\", \"@Type\": \"Clinical significance\", \"Description\": \"Pathogenic\", \"Citation\": [{\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"2170400\"}}, {\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"868875\"}}], \"ConditionList\": {\"TraitSet\": {\"@ID\": \"1061\", \"@Type\": \"Disease\", \"Trait\": {\"@ID\": \"10010\", \"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"Hexosaminidase B (paris)\"}}, \"XRef\": {\"@ID\": \"C4016989\", \"@DB\": \"MedGen\"}}}}}}, \"ClinicalAssertionList\": {\"ClinicalAssertion\": {\"@ID\": \"24246\", \"@DateCreated\": \"2011-01-25\", \"@DateLastUpdated\": \"2019-03-31\", \"@SubmissionDate\": \"2010-12-30\", \"ClinVarSubmissionID\": {\"@localKey\": \"606873.0003_HEXOSAMINIDASE B (PARIS)\", \"@title\": \"HEXB, 18-BP INS_HEXOSAMINIDASE B (PARIS)\"}, \"ClinVarAccession\": {\"@Accession\": \"SCV000024246\", \"@Type\": \"SCV\", \"@Version\": \"1\", \"@SubmitterName\": \"OMIM\", \"@OrgID\": \"3\", \"@OrganizationCategory\": \"resource\"}, \"RecordStatus\": \"current\", \"ReviewStatus\": \"no assertion criteria provided\", \"Interpretation\": {\"@DateLastEvaluated\": \"1990-10-15\", \"Description\": \"Pathogenic\"}, \"Assertion\": \"variation to disease\", \"ObservedInList\": {\"ObservedIn\": {\"Sample\": {\"Origin\": \"germline\", \"Species\": \"human\", \"AffectedStatus\": \"not provided\"}, \"Method\": {\"MethodType\": \"literature only\"}, \"ObservedData\": {\"Attribute\": {\"@Type\": \"Description\", \"#text\": \"Dreyfus et al. (1977) characterized a hexosaminidase variant that may represent unstable beta subunits. Dlott et al. (1990) demonstrated that this so-called 'hexosaminidase Paris' had an abnormally elongated beta subunit due to duplication of a region straddling the junction of intron 13 and exon 14, which generated an alternate splice site and caused an in-frame insertion of 18 nucleotides into the mRNA. The normal splice site seemed to be used to some extent, accounting for the residual Hex-A isoenzyme activity.\"}, \"Citation\": [{\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"868875\"}}, {\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"2170400\"}}]}}}, \"SimpleAllele\": {\"GeneList\": {\"Gene\": {\"@Symbol\": \"HEXB\"}}, \"Name\": \"HEXB, 18-BP INS\", \"VariantType\": \"Variation\", \"OtherNameList\": {\"Name\": {\"@Type\": \"NonHGVS\", \"#text\": \"18-BP INS\"}}, \"XRefList\": {\"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"606873.0003\", \"@Type\": \"Allelic variant\"}}}, \"TraitSet\": {\"@Type\": \"Disease\", \"Trait\": {\"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"HEXOSAMINIDASE B (PARIS)\"}}}}}}, \"TraitMappingList\": {\"TraitMapping\": {\"@ClinicalAssertionID\": \"24246\", \"@TraitType\": \"Disease\", \"@MappingType\": \"Name\", \"@MappingValue\": \"HEXOSAMINIDASE B (PARIS)\", \"@MappingRef\": \"Preferred\", \"MedGen\": {\"@CUI\": \"C4016989\", \"@Name\": \"Hexosaminidase B (paris)\"}}}}}\n",
            "{\"RecordStatus\": \"current\", \"Species\": \"Homo sapiens\", \"InterpretedRecord\": {\"SimpleAllele\": {\"@AlleleID\": \"19832\", \"@VariationID\": \"4793\", \"GeneList\": {\"Gene\": {\"@Symbol\": \"PRX\", \"@FullName\": \"periaxin\", \"@GeneID\": \"57716\", \"@HGNC_ID\": \"HGNC:13797\", \"@Source\": \"submitted\", \"@RelationshipType\": \"asserted, but not computed\", \"Location\": {\"CytogeneticLocation\": \"19q13.2\", \"SequenceLocation\": [{\"@Assembly\": \"GRCh38\", \"@AssemblyAccessionVersion\": \"GCF_000001405.38\", \"@AssemblyStatus\": \"current\", \"@Chr\": \"19\", \"@Accession\": \"NC_000019.10\", \"@start\": \"40393762\", \"@stop\": \"40414718\", \"@display_start\": \"40393762\", \"@display_stop\": \"40414718\", \"@Strand\": \"-\"}, {\"@Assembly\": \"GRCh37\", \"@AssemblyAccessionVersion\": \"GCF_000001405.25\", \"@AssemblyStatus\": \"previous\", \"@Chr\": \"19\", \"@Accession\": \"NC_000019.9\", \"@start\": \"40899670\", \"@stop\": \"40919270\", \"@display_start\": \"40899670\", \"@display_stop\": \"40919270\", \"@Strand\": \"-\"}]}, \"OMIM\": \"605725\"}}, \"Name\": \"PRX, 1-BP DEL, 247C\", \"VariantType\": \"Deletion\", \"Location\": {\"CytogeneticLocation\": \"19q13.1-q13.2\"}, \"OtherNameList\": {\"Name\": \"1-BP DEL, 247C\"}, \"XRefList\": {\"XRef\": {\"@Type\": \"Allelic variant\", \"@ID\": \"605725.0007\", \"@DB\": \"OMIM\"}}}, \"ReviewStatus\": \"no assertion criteria provided\", \"RCVList\": {\"RCVAccession\": {\"@Title\": \"PRX, 1-BP DEL, 247C AND Autosomal recessive Dejerine-Sottas syndrome\", \"@DateLastEvaluated\": \"2002-06-01\", \"@ReviewStatus\": \"no assertion criteria provided\", \"@Interpretation\": \"Pathogenic\", \"@SubmissionCount\": \"1\", \"@Accession\": \"RCV000005060\", \"@Version\": \"3\", \"InterpretedConditionList\": {\"@TraitSetID\": \"2323\", \"InterpretedCondition\": {\"@DB\": \"MedGen\", \"@ID\": \"CN069172\", \"#text\": \"Autosomal recessive Dejerine-Sottas syndrome\"}}}}, \"Interpretations\": {\"Interpretation\": {\"@DateLastEvaluated\": \"2002-06-01\", \"@NumberOfSubmissions\": \"1\", \"@NumberOfSubmitters\": \"1\", \"@Type\": \"Clinical significance\", \"Description\": \"Pathogenic\", \"Citation\": {\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"12112076\"}}, \"ConditionList\": {\"TraitSet\": {\"@ID\": \"2323\", \"@Type\": \"Disease\", \"Trait\": {\"@ID\": \"10445\", \"@Type\": \"Disease\", \"Name\": [{\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"Autosomal recessive Dejerine-Sottas syndrome\"}}, {\"ElementValue\": {\"@Type\": \"Alternate\", \"#text\": \"Autosomal recessive Dejerine-sottas neuropathy\"}}], \"XRef\": {\"@ID\": \"CN069172\", \"@DB\": \"MedGen\"}}}}}}, \"ClinicalAssertionList\": {\"ClinicalAssertion\": {\"@ID\": \"25236\", \"@DateCreated\": \"2011-01-25\", \"@DateLastUpdated\": \"2019-03-31\", \"@SubmissionDate\": \"2010-12-30\", \"ClinVarSubmissionID\": {\"@localKey\": \"605725.0007_DEJERINE-SOTTAS NEUROPATHY, AUTOSOMAL RECESSIVE\", \"@title\": \"PRX, 1-BP DEL, 247C_DEJERINE-SOTTAS NEUROPATHY, AUTOSOMAL RECESSIVE\"}, \"ClinVarAccession\": {\"@Accession\": \"SCV000025236\", \"@Type\": \"SCV\", \"@Version\": \"2\", \"@SubmitterName\": \"OMIM\", \"@OrgID\": \"3\", \"@OrganizationCategory\": \"resource\"}, \"RecordStatus\": \"current\", \"ReviewStatus\": \"no assertion criteria provided\", \"Interpretation\": {\"@DateLastEvaluated\": \"2002-06-01\", \"Description\": \"Pathogenic\"}, \"Assertion\": \"variation to disease\", \"ObservedInList\": {\"ObservedIn\": {\"Sample\": {\"Origin\": \"germline\", \"Species\": \"human\", \"AffectedStatus\": \"not provided\"}, \"Method\": {\"MethodType\": \"literature only\"}, \"ObservedData\": {\"Attribute\": {\"@Type\": \"Description\", \"#text\": \"In a patient with Dejerine-Sottas neuropathy (145900), the offspring of consanguineous parents, Takashima et al. (2002) found homozygosity for deletion of 1 bp (247delC) in the PRX gene, resulting in a frameshift and a stop codon at residue 96 (Arg82fsTer96).\"}, \"Citation\": {\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"12112076\"}}, \"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"145900\", \"@Type\": \"MIM\"}}}}, \"SimpleAllele\": {\"GeneList\": {\"Gene\": {\"@Symbol\": \"PRX\"}}, \"Name\": \"PRX, 1-BP DEL, 247C\", \"VariantType\": \"Variation\", \"OtherNameList\": {\"Name\": {\"@Type\": \"NonHGVS\", \"#text\": \"1-BP DEL, 247C\"}}, \"XRefList\": {\"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"605725.0007\", \"@Type\": \"Allelic variant\"}}}, \"TraitSet\": {\"@Type\": \"Disease\", \"Trait\": {\"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"DEJERINE-SOTTAS NEUROPATHY, AUTOSOMAL RECESSIVE\"}}}}}}, \"TraitMappingList\": {\"TraitMapping\": {\"@ClinicalAssertionID\": \"25236\", \"@TraitType\": \"Disease\", \"@MappingType\": \"Name\", \"@MappingValue\": \"DEJERINE-SOTTAS NEUROPATHY, AUTOSOMAL RECESSIVE\", \"@MappingRef\": \"Preferred\", \"MedGen\": {\"@CUI\": \"CN069172\", \"@Name\": \"Autosomal recessive Dejerine-Sottas syndrome\"}}}}}\n",
            "{\"RecordStatus\": \"current\", \"Species\": \"Homo sapiens\", \"InterpretedRecord\": {\"SimpleAllele\": {\"@AlleleID\": \"20217\", \"@VariationID\": \"5178\", \"GeneList\": {\"Gene\": {\"@Symbol\": \"ADCY10\", \"@FullName\": \"adenylate cyclase 10\", \"@GeneID\": \"55811\", \"@HGNC_ID\": \"HGNC:21285\", \"@Source\": \"submitted\", \"@RelationshipType\": \"asserted, but not computed\", \"Location\": {\"CytogeneticLocation\": \"1q24.2\", \"SequenceLocation\": [{\"@Assembly\": \"GRCh38\", \"@AssemblyAccessionVersion\": \"GCF_000001405.38\", \"@AssemblyStatus\": \"current\", \"@Chr\": \"1\", \"@Accession\": \"NC_000001.11\", \"@start\": \"167809080\", \"@stop\": \"167916389\", \"@display_start\": \"167809080\", \"@display_stop\": \"167916389\", \"@Strand\": \"-\"}, {\"@Assembly\": \"GRCh37\", \"@AssemblyAccessionVersion\": \"GCF_000001405.25\", \"@AssemblyStatus\": \"previous\", \"@Chr\": \"1\", \"@Accession\": \"NC_000001.10\", \"@start\": \"167778624\", \"@stop\": \"167883452\", \"@display_start\": \"167778624\", \"@display_stop\": \"167883452\", \"@Strand\": \"-\"}]}, \"OMIM\": \"605205\"}}, \"Name\": \"ADCY10, 923C-T\", \"VariantType\": \"single nucleotide variant\", \"Location\": {\"CytogeneticLocation\": \"1q24\"}, \"OtherNameList\": {\"Name\": \"923C-T\"}, \"XRefList\": {\"XRef\": {\"@Type\": \"Allelic variant\", \"@ID\": \"605205.0001\", \"@DB\": \"OMIM\"}}}, \"ReviewStatus\": \"no assertion criteria provided\", \"RCVList\": {\"RCVAccession\": {\"@Title\": \"ADCY10, 923C-T AND Hypercalciuria, absorptive, susceptibility to\", \"@DateLastEvaluated\": \"2002-04-01\", \"@ReviewStatus\": \"no assertion criteria provided\", \"@Interpretation\": \"risk factor\", \"@SubmissionCount\": \"1\", \"@Accession\": \"RCV000005486\", \"@Version\": \"4\", \"InterpretedConditionList\": {\"@TraitSetID\": \"1429\", \"InterpretedCondition\": \"Hypercalciuria, absorptive, susceptibility to\"}}}, \"Interpretations\": {\"Interpretation\": {\"@DateLastEvaluated\": \"2002-04-01\", \"@NumberOfSubmissions\": \"1\", \"@NumberOfSubmitters\": \"1\", \"@Type\": \"Clinical significance\", \"Description\": \"risk factor\", \"Citation\": {\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"11932268\"}}, \"ConditionList\": {\"TraitSet\": {\"@ID\": \"1429\", \"@Type\": \"Disease\", \"Trait\": {\"@ID\": \"10140\", \"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"Hypercalciuria, absorptive, susceptibility to\"}}}}}}}, \"ClinicalAssertionList\": {\"ClinicalAssertion\": {\"@ID\": \"25668\", \"@DateCreated\": \"2011-01-25\", \"@DateLastUpdated\": \"2019-03-31\", \"@SubmissionDate\": \"2010-12-30\", \"ClinVarSubmissionID\": {\"@localKey\": \"605205.0001_HYPERCALCIURIA, ABSORPTIVE, SUSCEPTIBILITY TO\", \"@title\": \"ADCY10, 923C-T_HYPERCALCIURIA, ABSORPTIVE, SUSCEPTIBILITY TO\"}, \"ClinVarAccession\": {\"@Accession\": \"SCV000025668\", \"@Type\": \"SCV\", \"@Version\": \"3\", \"@SubmitterName\": \"OMIM\", \"@OrgID\": \"3\", \"@OrganizationCategory\": \"resource\"}, \"RecordStatus\": \"current\", \"ReviewStatus\": \"no assertion criteria provided\", \"Interpretation\": {\"@DateLastEvaluated\": \"2002-04-01\", \"Description\": \"risk factor\"}, \"Assertion\": \"variation to disease\", \"ObservedInList\": {\"ObservedIn\": {\"Sample\": {\"Origin\": \"germline\", \"Species\": \"human\", \"AffectedStatus\": \"not provided\"}, \"Method\": {\"MethodType\": \"literature only\"}, \"ObservedData\": {\"Attribute\": {\"@Type\": \"Description\", \"#text\": \"Reed et al. (2002) performed mutation analysis of the ADCY10 gene in subjects with absorptive hypercalciuria (see HCA2, 143870) and found a 923C-T base substitution in exon 7 that changed a threonine to a methionine. This base substitution was 1 of 6 that occurred with significantly increased frequency in their HCA patient population. The presence of this substitution in 1 or both alleles was associated with a 3.1-fold increase in estimated risk for stone formation and occurrence of the HCA phenotype.\"}, \"Citation\": {\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"11932268\"}}, \"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"143870\", \"@Type\": \"MIM\"}}}}, \"SimpleAllele\": {\"GeneList\": {\"Gene\": {\"@Symbol\": \"ADCY10\"}}, \"Name\": \"ADCY10, 923C-T\", \"VariantType\": \"Variation\", \"OtherNameList\": {\"Name\": {\"@Type\": \"NonHGVS\", \"#text\": \"923C-T\"}}, \"XRefList\": {\"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"605205.0001\", \"@Type\": \"Allelic variant\"}}}, \"TraitSet\": {\"@Type\": \"Disease\", \"Trait\": {\"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"HYPERCALCIURIA, ABSORPTIVE, SUSCEPTIBILITY TO\"}}}}}}, \"TraitMappingList\": {\"TraitMapping\": {\"@ClinicalAssertionID\": \"25668\", \"@TraitType\": \"Disease\", \"@MappingType\": \"Name\", \"@MappingValue\": \"HYPERCALCIURIA, ABSORPTIVE, SUSCEPTIBILITY TO\", \"@MappingRef\": \"Preferred\", \"MedGen\": {\"@CUI\": \"C4016921\", \"@Name\": \"Hypercalciuria, absorptive, susceptibility to\"}}}}}\n",
            "{\"RecordStatus\": \"current\", \"Species\": \"Homo sapiens\", \"InterpretedRecord\": {\"SimpleAllele\": {\"@AlleleID\": \"20218\", \"@VariationID\": \"5179\", \"GeneList\": {\"Gene\": {\"@Symbol\": \"ADCY10\", \"@FullName\": \"adenylate cyclase 10\", \"@GeneID\": \"55811\", \"@HGNC_ID\": \"HGNC:21285\", \"@Source\": \"submitted\", \"@RelationshipType\": \"asserted, but not computed\", \"Location\": {\"CytogeneticLocation\": \"1q24.2\", \"SequenceLocation\": [{\"@Assembly\": \"GRCh38\", \"@AssemblyAccessionVersion\": \"GCF_000001405.38\", \"@AssemblyStatus\": \"current\", \"@Chr\": \"1\", \"@Accession\": \"NC_000001.11\", \"@start\": \"167809080\", \"@stop\": \"167916389\", \"@display_start\": \"167809080\", \"@display_stop\": \"167916389\", \"@Strand\": \"-\"}, {\"@Assembly\": \"GRCh37\", \"@AssemblyAccessionVersion\": \"GCF_000001405.25\", \"@AssemblyStatus\": \"previous\", \"@Chr\": \"1\", \"@Accession\": \"NC_000001.10\", \"@start\": \"167778624\", \"@stop\": \"167883452\", \"@display_start\": \"167778624\", \"@display_stop\": \"167883452\", \"@Strand\": \"-\"}]}, \"OMIM\": \"605205\"}}, \"Name\": \"ADCY10, 1438+30T-C\", \"VariantType\": \"single nucleotide variant\", \"Location\": {\"CytogeneticLocation\": \"1q24\"}, \"OtherNameList\": {\"Name\": \"1438+30T-C\"}, \"XRefList\": {\"XRef\": {\"@Type\": \"Allelic variant\", \"@ID\": \"605205.0002\", \"@DB\": \"OMIM\"}}}, \"ReviewStatus\": \"no assertion criteria provided\", \"RCVList\": {\"RCVAccession\": {\"@Title\": \"ADCY10, 1438+30T-C AND Hypercalciuria, absorptive, susceptibility to\", \"@DateLastEvaluated\": \"2002-04-01\", \"@ReviewStatus\": \"no assertion criteria provided\", \"@Interpretation\": \"risk factor\", \"@SubmissionCount\": \"1\", \"@Accession\": \"RCV000005487\", \"@Version\": \"4\", \"InterpretedConditionList\": {\"@TraitSetID\": \"1429\", \"InterpretedCondition\": \"Hypercalciuria, absorptive, susceptibility to\"}}}, \"Interpretations\": {\"Interpretation\": {\"@DateLastEvaluated\": \"2002-04-01\", \"@NumberOfSubmissions\": \"1\", \"@NumberOfSubmitters\": \"1\", \"@Type\": \"Clinical significance\", \"Description\": \"risk factor\", \"Citation\": {\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"11932268\"}}, \"ConditionList\": {\"TraitSet\": {\"@ID\": \"1429\", \"@Type\": \"Disease\", \"Trait\": {\"@ID\": \"10140\", \"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"Hypercalciuria, absorptive, susceptibility to\"}}}}}}}, \"ClinicalAssertionList\": {\"ClinicalAssertion\": {\"@ID\": \"25669\", \"@DateCreated\": \"2011-01-25\", \"@DateLastUpdated\": \"2019-03-31\", \"@SubmissionDate\": \"2010-12-30\", \"ClinVarSubmissionID\": {\"@localKey\": \"605205.0002_HYPERCALCIURIA, ABSORPTIVE, SUSCEPTIBILITY TO\", \"@title\": \"ADCY10, 1438+30T-C_HYPERCALCIURIA, ABSORPTIVE, SUSCEPTIBILITY TO\"}, \"ClinVarAccession\": {\"@Accession\": \"SCV000025669\", \"@Type\": \"SCV\", \"@Version\": \"3\", \"@SubmitterName\": \"OMIM\", \"@OrgID\": \"3\", \"@OrganizationCategory\": \"resource\"}, \"RecordStatus\": \"current\", \"ReviewStatus\": \"no assertion criteria provided\", \"Interpretation\": {\"@DateLastEvaluated\": \"2002-04-01\", \"Description\": \"risk factor\"}, \"Assertion\": \"variation to disease\", \"ObservedInList\": {\"ObservedIn\": {\"Sample\": {\"Origin\": \"germline\", \"Species\": \"human\", \"AffectedStatus\": \"not provided\"}, \"Method\": {\"MethodType\": \"literature only\"}, \"ObservedData\": {\"Attribute\": {\"@Type\": \"Description\", \"#text\": \"Reed et al. (2002) found that a 1438+30T-C base substitution in intron 11 of the ADCY10 gene, 1 of 6 mutations that occurred with increased frequency in their population of patients with HCA (see HCA2, 143870), was associated with a 3.2-fold increase in estimated risk for stone formation and occurrence of the HCA phenotype.\"}, \"Citation\": {\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"11932268\"}}, \"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"143870\", \"@Type\": \"MIM\"}}}}, \"SimpleAllele\": {\"GeneList\": {\"Gene\": {\"@Symbol\": \"ADCY10\"}}, \"Name\": \"ADCY10, 1438+30T-C\", \"VariantType\": \"Variation\", \"OtherNameList\": {\"Name\": {\"@Type\": \"NonHGVS\", \"#text\": \"1438+30T-C\"}}, \"XRefList\": {\"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"605205.0002\", \"@Type\": \"Allelic variant\"}}}, \"TraitSet\": {\"@Type\": \"Disease\", \"Trait\": {\"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"HYPERCALCIURIA, ABSORPTIVE, SUSCEPTIBILITY TO\"}}}}}}, \"TraitMappingList\": {\"TraitMapping\": {\"@ClinicalAssertionID\": \"25669\", \"@TraitType\": \"Disease\", \"@MappingType\": \"Name\", \"@MappingValue\": \"HYPERCALCIURIA, ABSORPTIVE, SUSCEPTIBILITY TO\", \"@MappingRef\": \"Preferred\", \"MedGen\": {\"@CUI\": \"C4016921\", \"@Name\": \"Hypercalciuria, absorptive, susceptibility to\"}}}}}\n",
            "{\"RecordStatus\": \"current\", \"Species\": \"Homo sapiens\", \"InterpretedRecord\": {\"SimpleAllele\": {\"@AlleleID\": \"22686\", \"@VariationID\": \"7647\", \"GeneList\": {\"Gene\": {\"@Symbol\": \"RFX5\", \"@FullName\": \"regulatory factor X5\", \"@GeneID\": \"5993\", \"@HGNC_ID\": \"HGNC:9986\", \"@Source\": \"submitted\", \"@RelationshipType\": \"asserted, but not computed\", \"Location\": {\"CytogeneticLocation\": \"1q21.3\", \"SequenceLocation\": [{\"@Assembly\": \"GRCh38\", \"@AssemblyAccessionVersion\": \"GCF_000001405.38\", \"@AssemblyStatus\": \"current\", \"@Chr\": \"1\", \"@Accession\": \"NC_000001.11\", \"@start\": \"151340640\", \"@stop\": \"151347319\", \"@display_start\": \"151340640\", \"@display_stop\": \"151347319\", \"@Strand\": \"-\"}, {\"@Assembly\": \"GRCh37\", \"@AssemblyAccessionVersion\": \"GCF_000001405.25\", \"@AssemblyStatus\": \"previous\", \"@Chr\": \"1\", \"@Accession\": \"NC_000001.10\", \"@start\": \"151313115\", \"@stop\": \"151319768\", \"@display_start\": \"151313115\", \"@display_stop\": \"151319768\", \"@Strand\": \"-\"}]}, \"OMIM\": \"601863\"}}, \"Name\": \"RFX5, 4-BP DEL, IVS-AS, G-A, -1\", \"VariantType\": \"Deletion\", \"Location\": {\"CytogeneticLocation\": \"1q21.1-q21.3\"}, \"OtherNameList\": {\"Name\": \"4-BP DEL, IVS-AS, G-A, -1\"}, \"XRefList\": {\"XRef\": {\"@Type\": \"Allelic variant\", \"@ID\": \"601863.0004\", \"@DB\": \"OMIM\"}}}, \"ReviewStatus\": \"no assertion criteria provided\", \"RCVList\": {\"RCVAccession\": {\"@Title\": \"RFX5, 4-BP DEL, IVS-AS, G-A, -1 AND Bare lymphocyte syndrome, type II, complementation group c\", \"@DateLastEvaluated\": \"1999-04-01\", \"@ReviewStatus\": \"no assertion criteria provided\", \"@Interpretation\": \"Pathogenic\", \"@SubmissionCount\": \"1\", \"@Accession\": \"RCV000008086\", \"@Version\": \"2\", \"InterpretedConditionList\": {\"@TraitSetID\": \"2085\", \"InterpretedCondition\": {\"@DB\": \"MedGen\", \"@ID\": \"C1859536\", \"#text\": \"Bare lymphocyte syndrome, type II, complementation group c\"}}}}, \"Interpretations\": {\"Interpretation\": {\"@DateLastEvaluated\": \"1999-04-01\", \"@NumberOfSubmissions\": \"1\", \"@NumberOfSubmitters\": \"1\", \"@Type\": \"Clinical significance\", \"Description\": \"Pathogenic\", \"Citation\": {\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"10079298\"}}, \"ConditionList\": {\"TraitSet\": {\"@ID\": \"2085\", \"@Type\": \"Disease\", \"Trait\": {\"@ID\": \"8786\", \"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"Bare lymphocyte syndrome, type II, complementation group c\"}}, \"AttributeSet\": {\"Attribute\": {\"@Type\": \"public definition\", \"#text\": \"Bare lymphocyte syndrome type II (BLS II) is an inherited disorder of the immune system categorized as a form of combined immunodeficiency (CID). People with BLS II lack virtually all immune protection from bacteria, viruses, and fungi. They are prone to repeated and persistent infections that can be very serious or life-threatening. These infections are often caused by \\\"opportunistic\\\" organisms that ordinarily do not cause illness in people with a normal immune system.BLS II is typically diagnosed in the first year of life. Most affected infants have persistent infections in the respiratory, gastrointestinal, and urinary tracts. Because of the infections, affected infants have difficulty absorbing nutrients (malabsorption), and they grow more slowly than their peers. Eventually, the persistent infections lead to organ failure. Without treatment, individuals with BLS II usually do not survive past early childhood.In people with BLS II, infection-fighting white blood cells (lymphocytes) are missing specialized proteins on their surface called major histocompatibility complex (MHC) class II proteins, which is where the condition got its name. Because BLS II is the most common and best studied form of a group of related conditions, it is often referred to as simply bare lymphocyte syndrome (BLS).\"}, \"XRef\": {\"@ID\": \"bare-lymphocyte-syndrome-type-ii\", \"@DB\": \"Genetics Home Reference\"}}, \"XRef\": {\"@ID\": \"C1859536\", \"@DB\": \"MedGen\"}}}}}}, \"ClinicalAssertionList\": {\"ClinicalAssertion\": {\"@ID\": \"28291\", \"@DateCreated\": \"2011-01-25\", \"@DateLastUpdated\": \"2019-03-31\", \"@SubmissionDate\": \"2010-12-30\", \"ClinVarSubmissionID\": {\"@localKey\": \"601863.0004_BARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP C\", \"@title\": \"RFX5, 4-BP DEL, IVS-AS, G-A, -1  _BARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP C\"}, \"ClinVarAccession\": {\"@Accession\": \"SCV000028291\", \"@Type\": \"SCV\", \"@Version\": \"1\", \"@SubmitterName\": \"OMIM\", \"@OrgID\": \"3\", \"@OrganizationCategory\": \"resource\"}, \"RecordStatus\": \"current\", \"ReviewStatus\": \"no assertion criteria provided\", \"Interpretation\": {\"@DateLastEvaluated\": \"1999-04-01\", \"Description\": \"Pathogenic\"}, \"Assertion\": \"variation to disease\", \"ObservedInList\": {\"ObservedIn\": {\"Sample\": {\"Origin\": \"germline\", \"Species\": \"human\", \"AffectedStatus\": \"not provided\"}, \"Method\": {\"MethodType\": \"literature only\"}, \"ObservedData\": {\"Attribute\": {\"@Type\": \"Description\", \"#text\": \"Peijnenburg et al. (1999) fused fibroblasts of a patient with bare lymphocyte syndrome type II, complementation group C (209920), with fibroblasts derived from patients representative of each of the 4 complementation groups. Transient heterokaryon analysis indicated that the patient belonged to complementation group C. Furthermore, transfection of wildtype RFX5 cDNA into the patient's fibroblasts resulted in correction of the defect. Mutation analysis revealed that the RFX5 mRNA lacked 4 nucleotides and that this deletion was a consequence of a G-to-A transition in a splice acceptor site. The patient was found to be homozygous for the splice site mutation. The nucleotides deleted were CAAG at positions 312-315 of the RFX5 cDNA. The deletion led to a frameshift and an out of frame stop codon located at nucleotides 403-405 of the wildtype RFX5 cDNA sequence. As a result, the mutated RFX5 mRNA encoded a truncated protein of 82 amino acids which lacked the DNA binding domain (DBD). The presence of the G-to-A point mutation and the use of a cryptic splice acceptor site (aCAAG) apparently resulted in an RFX5 mRNA from which 4 nucleotides of the particular exon were spliced out. Both parents were heterozygous for the mutation.\"}, \"Citation\": {\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"10079298\"}}, \"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"209920\", \"@Type\": \"MIM\"}}}}, \"SimpleAllele\": {\"GeneList\": {\"Gene\": {\"@Symbol\": \"RFX5\"}}, \"Name\": \"RFX5, 4-BP DEL, IVS-AS, G-A, -1\", \"VariantType\": \"Variation\", \"OtherNameList\": {\"Name\": {\"@Type\": \"NonHGVS\", \"#text\": \"4-BP DEL, IVS-AS, G-A, -1\"}}, \"XRefList\": {\"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"601863.0004\", \"@Type\": \"Allelic variant\"}}}, \"TraitSet\": {\"@Type\": \"Disease\", \"Trait\": {\"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"BARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP C\"}}}}}}, \"TraitMappingList\": {\"TraitMapping\": {\"@ClinicalAssertionID\": \"28291\", \"@TraitType\": \"Disease\", \"@MappingType\": \"Name\", \"@MappingValue\": \"BARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP C\", \"@MappingRef\": \"Preferred\", \"MedGen\": {\"@CUI\": \"C1859536\", \"@Name\": \"Bare lymphocyte syndrome, type II, complementation group c\"}}}}}\n",
            "{\"RecordStatus\": \"current\", \"Species\": \"Homo sapiens\", \"InterpretedRecord\": {\"SimpleAllele\": {\"@AlleleID\": \"23218\", \"@VariationID\": \"8179\", \"GeneList\": {\"Gene\": {\"@Symbol\": \"CTRC\", \"@FullName\": \"chymotrypsin C\", \"@GeneID\": \"11330\", \"@HGNC_ID\": \"HGNC:2523\", \"@Source\": \"submitted\", \"@RelationshipType\": \"asserted, but not computed\", \"Location\": {\"CytogeneticLocation\": \"1p36.21\", \"SequenceLocation\": [{\"@Assembly\": \"GRCh38\", \"@AssemblyAccessionVersion\": \"GCF_000001405.38\", \"@AssemblyStatus\": \"current\", \"@Chr\": \"1\", \"@Accession\": \"NC_000001.11\", \"@start\": \"15438442\", \"@stop\": \"15449247\", \"@display_start\": \"15438442\", \"@display_stop\": \"15449247\", \"@Strand\": \"+\"}, {\"@Assembly\": \"GRCh37\", \"@AssemblyAccessionVersion\": \"GCF_000001405.25\", \"@AssemblyStatus\": \"previous\", \"@Chr\": \"1\", \"@Accession\": \"NC_000001.10\", \"@start\": \"15764937\", \"@stop\": \"15773152\", \"@display_start\": \"15764937\", \"@display_stop\": \"15773152\", \"@Strand\": \"+\"}]}, \"OMIM\": \"601405\"}}, \"Name\": \"CTRC, 24-BP DEL, NT738\", \"VariantType\": \"Deletion\", \"Location\": {\"CytogeneticLocation\": \"1p36.21\"}, \"OtherNameList\": {\"Name\": \"24-BP DEL, NT738\"}, \"XRefList\": {\"XRef\": {\"@Type\": \"Allelic variant\", \"@ID\": \"601405.0002\", \"@DB\": \"OMIM\"}}}, \"ReviewStatus\": \"no assertion criteria provided\", \"RCVList\": {\"RCVAccession\": {\"@Title\": \"CTRC, 24-BP DEL, NT738 AND Pancreatitis, chronic, susceptibility to\", \"@DateLastEvaluated\": \"2008-02-01\", \"@ReviewStatus\": \"no assertion criteria provided\", \"@Interpretation\": \"risk factor\", \"@SubmissionCount\": \"1\", \"@Accession\": \"RCV000008658\", \"@Version\": \"2\", \"InterpretedConditionList\": {\"@TraitSetID\": \"2238\", \"InterpretedCondition\": {\"@DB\": \"MedGen\", \"@ID\": \"C1969419\", \"#text\": \"Pancreatitis, chronic, susceptibility to\"}}}}, \"Interpretations\": {\"Interpretation\": {\"@DateLastEvaluated\": \"2008-02-01\", \"@NumberOfSubmissions\": \"1\", \"@NumberOfSubmitters\": \"1\", \"@Type\": \"Clinical significance\", \"Description\": \"risk factor\", \"Citation\": [{\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"18059268\"}}, {\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"18172691\"}}], \"ConditionList\": {\"TraitSet\": {\"@ID\": \"2238\", \"@Type\": \"Disease\", \"Trait\": {\"@ID\": \"8552\", \"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"Pancreatitis, chronic, susceptibility to\"}}, \"XRef\": {\"@ID\": \"C1969419\", \"@DB\": \"MedGen\"}}}}}}, \"ClinicalAssertionList\": {\"ClinicalAssertion\": {\"@ID\": \"28867\", \"@DateCreated\": \"2011-01-25\", \"@DateLastUpdated\": \"2019-03-31\", \"@SubmissionDate\": \"2010-12-30\", \"ClinVarSubmissionID\": {\"@localKey\": \"601405.0002_PANCREATITIS, CHRONIC, SUSCEPTIBILITY TO\", \"@title\": \"CTRC, 24-BP DEL, NT738_PANCREATITIS, CHRONIC, SUSCEPTIBILITY TO\"}, \"ClinVarAccession\": {\"@Accession\": \"SCV000028867\", \"@Type\": \"SCV\", \"@Version\": \"1\", \"@SubmitterName\": \"OMIM\", \"@OrgID\": \"3\", \"@OrganizationCategory\": \"resource\"}, \"RecordStatus\": \"current\", \"ReviewStatus\": \"no assertion criteria provided\", \"Interpretation\": {\"@DateLastEvaluated\": \"2008-02-01\", \"Description\": \"risk factor\"}, \"Assertion\": \"variation to disease\", \"ObservedInList\": {\"ObservedIn\": {\"Sample\": {\"Origin\": \"germline\", \"Species\": \"human\", \"AffectedStatus\": \"not provided\"}, \"Method\": {\"MethodType\": \"literature only\"}, \"ObservedData\": [{\"Attribute\": {\"@Type\": \"Description\", \"#text\": \"Rosendahl et al. (2008) found that a 24-bp in-frame deletion in exon 7 of the CTRC gene (738_761del24, lys247_arg254del) was significantly overrepresented among 901 individuals of German origin with idiopathic or hereditary chronic pancreatitis (167800) (1.2%) compared to 2,804 German controls (0.1%, P = 0.00003). Allele frequency was 0.6% among 348 German individuals with alcohol-related chronic pancreatitis and 0.2% among 432 controls. This variant was not found among 71 Indian subjects with tropical pancreatitis (608189) and 84 controls of Indian origin.\"}, \"Citation\": {\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"18059268\"}}, \"XRef\": [{\"@DB\": \"OMIM\", \"@ID\": \"167800\", \"@Type\": \"MIM\"}, {\"@DB\": \"OMIM\", \"@ID\": \"608189\", \"@Type\": \"MIM\"}]}, {\"Attribute\": {\"@Type\": \"Description\", \"#text\": \"Masson et al. (2008) sequenced the CTRC gene in 287 white French patients with idiopathic chronic pancreatitis and identified the 24-bp deletion at nucleotide 738 in 2 sporadic patients and 1 of 350 controls.\"}, \"Citation\": {\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"18172691\"}}}]}}, \"SimpleAllele\": {\"GeneList\": {\"Gene\": {\"@Symbol\": \"CTRC\"}}, \"Name\": \"CTRC, 24-BP DEL, NT738\", \"VariantType\": \"Variation\", \"OtherNameList\": {\"Name\": {\"@Type\": \"NonHGVS\", \"#text\": \"24-BP DEL, NT738\"}}, \"XRefList\": {\"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"601405.0002\", \"@Type\": \"Allelic variant\"}}}, \"TraitSet\": {\"@Type\": \"Disease\", \"Trait\": {\"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"PANCREATITIS, CHRONIC, SUSCEPTIBILITY TO\"}}}}}}, \"TraitMappingList\": {\"TraitMapping\": {\"@ClinicalAssertionID\": \"28867\", \"@TraitType\": \"Disease\", \"@MappingType\": \"Name\", \"@MappingValue\": \"PANCREATITIS, CHRONIC, SUSCEPTIBILITY TO\", \"@MappingRef\": \"Preferred\", \"MedGen\": {\"@CUI\": \"C1969419\", \"@Name\": \"Pancreatitis, chronic, susceptibility to\"}}}}}\n",
            "{\"RecordStatus\": \"current\", \"Species\": \"Homo sapiens\", \"InterpretedRecord\": {\"SimpleAllele\": {\"@AlleleID\": \"23665\", \"@VariationID\": \"8626\", \"GeneList\": {\"Gene\": {\"@Symbol\": \"AMHR2\", \"@FullName\": \"anti-Mullerian hormone receptor type 2\", \"@GeneID\": \"269\", \"@HGNC_ID\": \"HGNC:465\", \"@Source\": \"submitted\", \"@RelationshipType\": \"asserted, but not computed\", \"Location\": {\"CytogeneticLocation\": \"12q13.13\", \"SequenceLocation\": [{\"@Assembly\": \"GRCh38\", \"@AssemblyAccessionVersion\": \"GCF_000001405.38\", \"@AssemblyStatus\": \"current\", \"@Chr\": \"12\", \"@Accession\": \"NC_000012.12\", \"@start\": \"53423855\", \"@stop\": \"53431672\", \"@display_start\": \"53423855\", \"@display_stop\": \"53431672\", \"@Strand\": \"+\"}, {\"@Assembly\": \"GRCh37\", \"@AssemblyAccessionVersion\": \"GCF_000001405.25\", \"@AssemblyStatus\": \"previous\", \"@Chr\": \"12\", \"@Accession\": \"NC_000012.11\", \"@start\": \"53817638\", \"@stop\": \"53825317\", \"@display_start\": \"53817638\", \"@display_stop\": \"53825317\", \"@Strand\": \"+\"}]}, \"OMIM\": \"600956\"}}, \"Name\": \"AMHR2, IVS2DS, G-T, +1\", \"VariantType\": \"single nucleotide variant\", \"Location\": {\"CytogeneticLocation\": \"12q13\"}, \"OtherNameList\": {\"Name\": \"IVS2DS, G-T, +1\"}, \"XRefList\": {\"XRef\": {\"@Type\": \"Allelic variant\", \"@ID\": \"600956.0001\", \"@DB\": \"OMIM\"}}}, \"ReviewStatus\": \"no assertion criteria provided\", \"RCVList\": {\"RCVAccession\": {\"@Title\": \"AMHR2, IVS2DS, G-T, +1 AND Persistent mullerian duct syndrome, type II\", \"@DateLastEvaluated\": \"1995-12-01\", \"@ReviewStatus\": \"no assertion criteria provided\", \"@Interpretation\": \"Pathogenic\", \"@SubmissionCount\": \"1\", \"@Accession\": \"RCV000009158\", \"@Version\": \"2\", \"InterpretedConditionList\": {\"@TraitSetID\": \"2370\", \"InterpretedCondition\": {\"@DB\": \"MedGen\", \"@ID\": \"C3897940\", \"#text\": \"Persistent mullerian duct syndrome, type II\"}}}}, \"Interpretations\": {\"Interpretation\": {\"@DateLastEvaluated\": \"1995-12-01\", \"@NumberOfSubmissions\": \"1\", \"@NumberOfSubmitters\": \"1\", \"@Type\": \"Clinical significance\", \"Description\": \"Pathogenic\", \"Citation\": {\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"7493017\"}}, \"ConditionList\": {\"TraitSet\": {\"@ID\": \"2370\", \"@Type\": \"Disease\", \"Trait\": {\"@ID\": \"10460\", \"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"Persistent mullerian duct syndrome, type II\"}}, \"XRef\": {\"@ID\": \"C3897940\", \"@DB\": \"MedGen\"}}}}}}, \"ClinicalAssertionList\": {\"ClinicalAssertion\": {\"@ID\": \"29375\", \"@DateCreated\": \"2011-01-25\", \"@DateLastUpdated\": \"2019-03-31\", \"@SubmissionDate\": \"2010-12-30\", \"ClinVarSubmissionID\": {\"@localKey\": \"600956.0001_PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II\", \"@title\": \"AMHR2, IVS2DS, G-T, +1_PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II\"}, \"ClinVarAccession\": {\"@Accession\": \"SCV000029375\", \"@Type\": \"SCV\", \"@Version\": \"1\", \"@SubmitterName\": \"OMIM\", \"@OrgID\": \"3\", \"@OrganizationCategory\": \"resource\"}, \"RecordStatus\": \"current\", \"ReviewStatus\": \"no assertion criteria provided\", \"Interpretation\": {\"@DateLastEvaluated\": \"1995-12-01\", \"Description\": \"Pathogenic\"}, \"Assertion\": \"variation to disease\", \"ObservedInList\": {\"ObservedIn\": {\"Sample\": {\"Origin\": \"germline\", \"Species\": \"human\", \"AffectedStatus\": \"not provided\"}, \"Method\": {\"MethodType\": \"literature only\"}, \"ObservedData\": {\"Attribute\": {\"@Type\": \"Description\", \"#text\": \"Imbeaud et al. (1995) demonstrated a G-to-A transition at position +1 of the splice donor site of intron 2 of the AMHR gene in a 3-month-old boy, born to allegedly unrelated Pakistani parents, who came to medical attention because of right cryptorchidism associated with a left inguinal hernia. At surgery, both testes were found in the left scrotum and inguinal canal, associated with a uterus and 2 fallopian tubes (see 261550). Biopsy showed normal seminiferous tubules containing germ cells. Normal regression of fetal rat mullerian ducts was elicited by coculture with a small testicular fragment, thus indicating that AMH was produced. Indeed, the AMH gene was sequenced and found to be normal in this patient. The G-to-A transition they found destroyed an HphI restriction site, allowing the determination of the genotype in the patient and his parents. The mutation was homozygous in the patient and both parents were heterozygotes. The mutation resulted in alternative splicing with production of 2 types of mRNA were produced: the shorter mRNA moiety showed skipping of the second exon with conservation of the reading frame; the longer one contained a 12-bp portion of intron 2, generated by the use of a cryptic donor sequence, GTATA, downstream of the splicing mutation. The result was a gly78-to-asp change of 1 amino acid followed by the insertion of 4 new residues, EWQR, at the end of exon 2.\"}, \"Citation\": {\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"7493017\"}}, \"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"261550\", \"@Type\": \"MIM\"}}}}, \"SimpleAllele\": {\"GeneList\": {\"Gene\": {\"@Symbol\": \"AMHR2\"}}, \"Name\": \"AMHR2, IVS2DS, G-T, +1\", \"VariantType\": \"Variation\", \"OtherNameList\": {\"Name\": {\"@Type\": \"NonHGVS\", \"#text\": \"IVS2DS, G-T, +1\"}}, \"XRefList\": {\"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"600956.0001\", \"@Type\": \"Allelic variant\"}}}, \"TraitSet\": {\"@Type\": \"Disease\", \"Trait\": {\"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II\"}}}}}}, \"TraitMappingList\": {\"TraitMapping\": {\"@ClinicalAssertionID\": \"29375\", \"@TraitType\": \"Disease\", \"@MappingType\": \"Name\", \"@MappingValue\": \"PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II\", \"@MappingRef\": \"Preferred\", \"MedGen\": {\"@CUI\": \"C3897940\", \"@Name\": \"Persistent mullerian duct syndrome, type II\"}}}}}\n",
            "{\"RecordStatus\": \"current\", \"Species\": \"Homo sapiens\", \"InterpretedRecord\": {\"SimpleAllele\": {\"@AlleleID\": \"23666\", \"@VariationID\": \"8627\", \"GeneList\": {\"Gene\": {\"@Symbol\": \"AMHR2\", \"@FullName\": \"anti-Mullerian hormone receptor type 2\", \"@GeneID\": \"269\", \"@HGNC_ID\": \"HGNC:465\", \"@Source\": \"submitted\", \"@RelationshipType\": \"asserted, but not computed\", \"Location\": {\"CytogeneticLocation\": \"12q13.13\", \"SequenceLocation\": [{\"@Assembly\": \"GRCh38\", \"@AssemblyAccessionVersion\": \"GCF_000001405.38\", \"@AssemblyStatus\": \"current\", \"@Chr\": \"12\", \"@Accession\": \"NC_000012.12\", \"@start\": \"53423855\", \"@stop\": \"53431672\", \"@display_start\": \"53423855\", \"@display_stop\": \"53431672\", \"@Strand\": \"+\"}, {\"@Assembly\": \"GRCh37\", \"@AssemblyAccessionVersion\": \"GCF_000001405.25\", \"@AssemblyStatus\": \"previous\", \"@Chr\": \"12\", \"@Accession\": \"NC_000012.11\", \"@start\": \"53817638\", \"@stop\": \"53825317\", \"@display_start\": \"53817638\", \"@display_stop\": \"53825317\", \"@Strand\": \"+\"}]}, \"OMIM\": \"600956\"}}, \"Name\": \"AMHR2, 27-BP DEL, NT6331\", \"VariantType\": \"Deletion\", \"Location\": {\"CytogeneticLocation\": \"12q13\"}, \"OtherNameList\": {\"Name\": \"27-BP DEL, NT6331\"}, \"XRefList\": {\"XRef\": {\"@Type\": \"Allelic variant\", \"@ID\": \"600956.0002\", \"@DB\": \"OMIM\"}}}, \"ReviewStatus\": \"no assertion criteria provided\", \"RCVList\": {\"RCVAccession\": {\"@Title\": \"AMHR2, 27-BP DEL, NT6331 AND Persistent mullerian duct syndrome, type II\", \"@DateLastEvaluated\": \"2009-08-15\", \"@ReviewStatus\": \"no assertion criteria provided\", \"@Interpretation\": \"Pathogenic\", \"@SubmissionCount\": \"1\", \"@Accession\": \"RCV000009159\", \"@Version\": \"2\", \"InterpretedConditionList\": {\"@TraitSetID\": \"2370\", \"InterpretedCondition\": {\"@DB\": \"MedGen\", \"@ID\": \"C3897940\", \"#text\": \"Persistent mullerian duct syndrome, type II\"}}}}, \"Interpretations\": {\"Interpretation\": {\"@DateLastEvaluated\": \"2009-08-15\", \"@NumberOfSubmissions\": \"1\", \"@NumberOfSubmitters\": \"1\", \"@Type\": \"Clinical significance\", \"Description\": \"Pathogenic\", \"Citation\": [{\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"19457927\"}}, {\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"8872466\"}}], \"ConditionList\": {\"TraitSet\": {\"@ID\": \"2370\", \"@Type\": \"Disease\", \"Trait\": {\"@ID\": \"10460\", \"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"Persistent mullerian duct syndrome, type II\"}}, \"XRef\": {\"@ID\": \"C3897940\", \"@DB\": \"MedGen\"}}}}}}, \"ClinicalAssertionList\": {\"ClinicalAssertion\": {\"@ID\": \"29376\", \"@DateCreated\": \"2011-01-25\", \"@DateLastUpdated\": \"2019-03-31\", \"@SubmissionDate\": \"2010-12-30\", \"ClinVarSubmissionID\": {\"@localKey\": \"600956.0002_PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II\", \"@title\": \"AMHR2, 27-BP DEL, NT6331 _PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II\"}, \"ClinVarAccession\": {\"@Accession\": \"SCV000029376\", \"@Type\": \"SCV\", \"@Version\": \"1\", \"@SubmitterName\": \"OMIM\", \"@OrgID\": \"3\", \"@OrganizationCategory\": \"resource\"}, \"RecordStatus\": \"current\", \"ReviewStatus\": \"no assertion criteria provided\", \"Interpretation\": {\"@DateLastEvaluated\": \"2009-08-15\", \"Description\": \"Pathogenic\"}, \"Assertion\": \"variation to disease\", \"ObservedInList\": {\"ObservedIn\": {\"Sample\": {\"Origin\": \"germline\", \"Species\": \"human\", \"AffectedStatus\": \"not provided\"}, \"Method\": {\"MethodType\": \"literature only\"}, \"ObservedData\": [{\"Attribute\": {\"@Type\": \"Description\", \"#text\": \"Imbeaud et al. (1996) detected a 27-bp deletion (6331_6357del) in exon 10 of the AMHR gene, on at least 1 allele in 10 of 16 patients studied with AMHR mutations. The deletion was homozygous in 4 patients and was coupled with missense mutations in 6 patients.\"}, \"Citation\": {\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"8872466\"}}}, {\"Attribute\": {\"@Type\": \"Description\", \"#text\": \"Belville et al. (2009) noted that the 6331_6357del is missing residues 444 to 452, which are located at the top of the C-lobe in the X region of the kinase domain. Molecular modeling predicted that the deletion should lead to a substantial conformational change in the AMHR2 fold, since the residues constitute part of the alpha-G helix and the loop that precedes it.\"}, \"Citation\": {\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"19457927\"}}}]}}, \"SimpleAllele\": {\"GeneList\": {\"Gene\": {\"@Symbol\": \"AMHR2\"}}, \"Name\": \"AMHR2, 27-BP DEL, NT6331\", \"VariantType\": \"Variation\", \"OtherNameList\": {\"Name\": {\"@Type\": \"NonHGVS\", \"#text\": \"27-BP DEL, NT6331\"}}, \"XRefList\": {\"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"600956.0002\", \"@Type\": \"Allelic variant\"}}}, \"TraitSet\": {\"@Type\": \"Disease\", \"Trait\": {\"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II\"}}}}}}, \"TraitMappingList\": {\"TraitMapping\": {\"@ClinicalAssertionID\": \"29376\", \"@TraitType\": \"Disease\", \"@MappingType\": \"Name\", \"@MappingValue\": \"PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II\", \"@MappingRef\": \"Preferred\", \"MedGen\": {\"@CUI\": \"C3897940\", \"@Name\": \"Persistent mullerian duct syndrome, type II\"}}}}}\n",
            "{\"RecordStatus\": \"current\", \"Species\": \"Homo sapiens\", \"InterpretedRecord\": {\"SimpleAllele\": {\"@AlleleID\": \"23667\", \"@VariationID\": \"8628\", \"GeneList\": {\"Gene\": {\"@Symbol\": \"AMHR2\", \"@FullName\": \"anti-Mullerian hormone receptor type 2\", \"@GeneID\": \"269\", \"@HGNC_ID\": \"HGNC:465\", \"@Source\": \"submitted\", \"@RelationshipType\": \"asserted, but not computed\", \"Location\": {\"CytogeneticLocation\": \"12q13.13\", \"SequenceLocation\": [{\"@Assembly\": \"GRCh38\", \"@AssemblyAccessionVersion\": \"GCF_000001405.38\", \"@AssemblyStatus\": \"current\", \"@Chr\": \"12\", \"@Accession\": \"NC_000012.12\", \"@start\": \"53423855\", \"@stop\": \"53431672\", \"@display_start\": \"53423855\", \"@display_stop\": \"53431672\", \"@Strand\": \"+\"}, {\"@Assembly\": \"GRCh37\", \"@AssemblyAccessionVersion\": \"GCF_000001405.25\", \"@AssemblyStatus\": \"previous\", \"@Chr\": \"12\", \"@Accession\": \"NC_000012.11\", \"@start\": \"53817638\", \"@stop\": \"53825317\", \"@display_start\": \"53817638\", \"@display_stop\": \"53825317\", \"@Strand\": \"+\"}]}, \"OMIM\": \"600956\"}}, \"Name\": \"AMHR2, 1-BP DEL, 1692A\", \"VariantType\": \"Deletion\", \"Location\": {\"CytogeneticLocation\": \"12q13\"}, \"OtherNameList\": {\"Name\": \"1-BP DEL, 1692A\"}, \"XRefList\": {\"XRef\": {\"@Type\": \"Allelic variant\", \"@ID\": \"600956.0003\", \"@DB\": \"OMIM\"}}}, \"ReviewStatus\": \"no assertion criteria provided\", \"RCVList\": {\"RCVAccession\": {\"@Title\": \"AMHR2, 1-BP DEL, 1692A AND Persistent mullerian duct syndrome, type II\", \"@DateLastEvaluated\": \"2009-08-15\", \"@ReviewStatus\": \"no assertion criteria provided\", \"@Interpretation\": \"Pathogenic\", \"@SubmissionCount\": \"1\", \"@Accession\": \"RCV000009160\", \"@Version\": \"2\", \"InterpretedConditionList\": {\"@TraitSetID\": \"2370\", \"InterpretedCondition\": {\"@DB\": \"MedGen\", \"@ID\": \"C3897940\", \"#text\": \"Persistent mullerian duct syndrome, type II\"}}}}, \"Interpretations\": {\"Interpretation\": {\"@DateLastEvaluated\": \"2009-08-15\", \"@NumberOfSubmissions\": \"1\", \"@NumberOfSubmitters\": \"1\", \"@Type\": \"Clinical significance\", \"Description\": \"Pathogenic\", \"Citation\": [{\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"11549681\"}}, {\"@Type\": \"general\", \"ID\": {\"@Source\": \"PubMed\", \"#text\": \"19457927\"}}], \"ConditionList\": {\"TraitSet\": {\"@ID\": \"2370\", \"@Type\": \"Disease\", \"Trait\": {\"@ID\": \"10460\", \"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"Persistent mullerian duct syndrome, type II\"}}, \"XRef\": {\"@ID\": \"C3897940\", \"@DB\": \"MedGen\"}}}}}}, \"ClinicalAssertionList\": {\"ClinicalAssertion\": {\"@ID\": \"29377\", \"@DateCreated\": \"2011-01-25\", \"@DateLastUpdated\": \"2019-03-31\", \"@SubmissionDate\": \"2010-12-30\", \"ClinVarSubmissionID\": {\"@localKey\": \"600956.0003_PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II\", \"@title\": \"AMHR2, 1-BP DEL, 1692A _PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II\"}, \"ClinVarAccession\": {\"@Accession\": \"SCV000029377\", \"@Type\": \"SCV\", \"@Version\": \"1\", \"@SubmitterName\": \"OMIM\", \"@OrgID\": \"3\", \"@OrganizationCategory\": \"resource\"}, \"RecordStatus\": \"current\", \"ReviewStatus\": \"no assertion criteria provided\", \"Interpretation\": {\"@DateLastEvaluated\": \"2009-08-15\", \"Description\": \"Pathogenic\"}, \"Assertion\": \"variation to disease\", \"ObservedInList\": {\"ObservedIn\": {\"Sample\": {\"Origin\": \"germline\", \"Species\": \"human\", \"AffectedStatus\": \"not provided\"}, \"Method\": {\"MethodType\": \"literature only\"}, \"ObservedData\": [{\"Attribute\": {\"@Type\": \"Description\", \"#text\": \"In a family with 2 members with persistent mullerian duct syndrome (261550) and one normal sib, Messika-Zeitoun et al. (2001) detected 2 novel mutations of the AMHR2 gene. One, transmitted by the mother to her 3 sons, was a deletion of an adenosine at nucleotide position 1692 in exon 5, leading to a stop codon and causing receptor truncation after the transmembrane domain. The other, a missense mutation in the substrate-binding site of the kinase domain (600956.0004), was transmitted by the father to the 2 affected sons, indicating a recessive autosomal transmission as in other cases of persistent mullerian duct syndrome. Truncating mutations in receptors of the TGF-beta family exert dominant-negative activity, which was seen only when each of the mutant anti-mullerian hormone receptors was overexpressed in an anti-mullerian hormone-responsive cell line. The authors concluded that assessment of dominant activity in vitro, which usually involves overexpression of mutant genes, does not necessarily produce information applicable to clinical conditions, in which mutant and endogenous genes are expressed on a one-to-one basis.\"}, \"Citation\": {\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"11549681\"}}, \"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"261550\", \"@Type\": \"MIM\"}}, {\"Attribute\": {\"@Type\": \"Description\", \"#text\": \"Belville et al. (2009) noted that the 1692delA mutation lacks the entire kinase domain and is therefore incapable of transducing an AMH signal.\"}, \"Citation\": {\"ID\": {\"@Source\": \"PubMed\", \"#text\": \"19457927\"}}}]}}, \"SimpleAllele\": {\"GeneList\": {\"Gene\": {\"@Symbol\": \"AMHR2\"}}, \"Name\": \"AMHR2, 1-BP DEL, 1692A\", \"VariantType\": \"Variation\", \"OtherNameList\": {\"Name\": {\"@Type\": \"NonHGVS\", \"#text\": \"1-BP DEL, 1692A\"}}, \"XRefList\": {\"XRef\": {\"@DB\": \"OMIM\", \"@ID\": \"600956.0003\", \"@Type\": \"Allelic variant\"}}}, \"TraitSet\": {\"@Type\": \"Disease\", \"Trait\": {\"@Type\": \"Disease\", \"Name\": {\"ElementValue\": {\"@Type\": \"Preferred\", \"#text\": \"PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II\"}}}}}}, \"TraitMappingList\": {\"TraitMapping\": {\"@ClinicalAssertionID\": \"29377\", \"@TraitType\": \"Disease\", \"@MappingType\": \"Name\", \"@MappingValue\": \"PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II\", \"@MappingRef\": \"Preferred\", \"MedGen\": {\"@CUI\": \"C3897940\", \"@Name\": \"Persistent mullerian duct syndrome, type II\"}}}}}\n"
          ]
        }
      ]
    }
  ]
}